Table 1 Baseline demographic and disease characteristics of the Chinese subpopulation of the JACOB trial (ITT population)
Characteristic | Total (cases) | Pertuzumab group [cases (%)] | Control group [cases (%)] |
|---|---|---|---|
Total | 163 | 82 | 81 |
Age | |||
 < 65 years |  | 61 (74.4) | 62 (76.5) |
 ≥ 65 years |  | 21 (25.6) | 19 (23.5) |
Sex | |||
 Male | 130 | 59 (72.0) | 71 (87.7) |
 Female | 33 | 23 (28.0) | 10 (12.3) |
Disease measurability | |||
 Measurable | 144 | 74 (90.2) | 70 (86.4) |
 Non-measurable | 19 | 8 (9.8) | 11 (13.6) |
ECOG PS | |||
 0 | 47 | 24 (29.3) | 23 (28.4) |
 1 | 116 | 58 (70.7) | 58 (71.6) |
Histological subtype (Lauren classification) | |||
 Diffuse | 16 | 9 (11.0) | 7 (8.6) |
 Intestinal | 144 | 71 (86.6) | 73 (90.1) |
 Mixed | 3 | 2 (2.4) | 1 (1.2) |
Primary site | |||
 Gastroesophageal junction | 33 | 21 (25.6) | 12 (14.8) |
 Stomach | 130 | 61 (74.4) | 69 (85.2) |
Number of metastatic sitesa | |||
 1–2 | 139 | 68 (82.9) | 71 (88.8) |
 > 2 | 23 | 14 (17.1) | 9 (11.3) |
HER status | |||
 IHC2+ and ISH+ | 31 | 14 (17.1) | 17 (21.0) |
 IHC3+ | 132 | 68 (82.9) | 64 (79.0) |
Prior gastrectomy | |||
 Yes | 47 | 23 (28.0) | 24 (29.6) |
 No | 116 | 59 (72.0) | 57 (70.4) |